Literature DB >> 12395109

Inhibition of voltage-gated Ca2+ channels by antazoline.

Didier Milhaud1, Laurent Fagni, Joël Bockaert, Mireille Lafon-Cazal.   

Abstract

We showed recently that imidazolines exert neuroprotection against hypoxia and NMDA toxicity in cerebellar and striatal neuronal cultures, through a voltage-dependent blockade of glutamatergic NMDA receptors. Here, we report that in striatal neuronal cultures from mouse embryos the imidazoline compound, antazoline, inhibits voltage-gated Ca2+ channels by acting at a phencyclidine-like site. This effect was fast, fully reversible, voltage-dependent and predominant on P/Q- and N-type Ca2+ channels. Taken together, these results suggest that imidazolines may elicit neuroprotective effects also by decreasing the release of glutamate through inhibition of presynaptic Ca2+ channels. Copyright 2002 Lippincott Williams & Wilkins

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12395109     DOI: 10.1097/00001756-200210070-00004

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  5 in total

Review 1.  P/Q-type calcium channel modulators.

Authors:  V Nimmrich; G Gross
Journal:  Br J Pharmacol       Date:  2012-10       Impact factor: 8.739

2.  Pentobarbital inhibition of human recombinant alpha1A P/Q-type voltage-gated calcium channels involves slow, open channel block.

Authors:  A Schober; E Sokolova; K J Gingrich
Journal:  Br J Pharmacol       Date:  2010-09       Impact factor: 8.739

3.  Histamine H3 receptor activation counteracts adenosine A2A receptor-mediated enhancement of depolarization-evoked [3H]-GABA release from rat globus pallidus synaptosomes.

Authors:  Guadalupe-Elide Morales-Figueroa; Ricardo Márquez-Gómez; Raúl González-Pantoja; Juan Escamilla-Sánchez; José-Antonio Arias-Montaño
Journal:  ACS Chem Neurosci       Date:  2014-06-11       Impact factor: 4.418

4.  Fast, non-competitive and reversible inhibition of NMDA-activated currents by 2-BFI confers neuroprotection.

Authors:  Zhao Han; Jin-Long Yang; Susan X Jiang; Sheng-Tao Hou; Rong-Yuan Zheng
Journal:  PLoS One       Date:  2013-05-31       Impact factor: 3.240

5.  Combined Treatment With 2-(2-Benzofu-Ranyl)-2-Imidazoline and Recombinant Tissue Plasminogen Activator Protects Blood-Brain Barrier Integrity in a Rat Model of Embolic Middle Cerebral Artery Occlusion.

Authors:  Linlei Zhang; Shasha Xu; Xiaoxiao Wu; Jiaou Chen; Xiaoling Guo; Yungang Cao; Zheng Zhang; Jueyue Yan; Jianhua Cheng; Zhao Han
Journal:  Front Pharmacol       Date:  2020-06-12       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.